feedback

Course Director

Jean A. Ridgeway, DNP, APN, NP-C, AOCN
Jean A. Ridgeway, DNP, APN, NP-C, AOCN

The University of Chicago Medicine
Chicago, Illinois

Faculty

Sandy Allen-Bard
Sandy Allen-Bard, MSN, NPc, ANCC, AOCNP

Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Emily A. Knight
Emily A. Knight, RN, MSN, NP, OCN

Mayo Clinic in Arizona
Mayo Clinic Cancer Center
Phoenix, Arizona

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CE
Credit Amount:1.5 Credits
Release Date:2017-Jun-07
Expiration Date:2018-Jul-06
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

Oncology nurse professionals play a key role in the management of patients with myeloproliferative neoplasms (MPNs), including those with myelofibrosis (MF) and polycythemia vera (PV). Modern management of MPNs involves new thinking on disease biology, optimal application of novel agent classes, and a risk-adapted approach to therapy that is tailored to the needs of individual patients. How do nurse professionals support and guide patients with MF or PV in their therapeutic journey while collaborating with the multidisciplinary team to effectively address practical issues that may arise during their care? This activity aims to provide an answer, and offers expert insights on best practices to educate patients on the nature and clinical burden of these diseases, and inform them regarding the benefits and risks of novel treatment options such as JAK inhibitors and their role in traditional treatment paradigms. Optimal use of available strategies to improve debilitating symptoms and enhance long-term care will also be discussed. A panel of top MPN experts engages participants in stimulating and interactive presentations within a framework of challenging case scenarios.

Upon completion of this activity, participants will be able to:
  • Discuss the clinical signs, symptoms, and potential complications associated with the spectrum of MPNs, including myelofibrosis (MF) and polycythemia vera (PV)
  • Educate patients on the efficacy and safety of current treatment options for MPNs, including for patients with low-, intermediate-, and high-risk MF, and high-risk or treatment-refractory PV
  • Collaborate with other members of the hematology-oncology management team in order to develop treatment strategies for patients with MF or PV
  • Manage dosing and safety considerations in patients with MF or PV on therapy

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, advanced practice oncology nurses, nurse practitioners, and other healthcare professionals involved in the care of patients with myeloproliferative neoplasms (MPNs).

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of myeloproliferative neoplasms.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 07, 2017 - June 06, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity during the past 12 months.

Course Director and Moderator
Jean A. Ridgeway, DNP, APN, NP-C, AOCN
Director of Advance Practice Providers, Hematology/Oncology
Advance Practice Nurse
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine
Chicago, Illinois

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with AbbVie; Celgene Corporation; and Pharmacyclics, Inc.
Advisory Board for Pharmacyclics, Inc.

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for myelofibrosis, polycythemia vera, and other myeloproliferative neoplasms.

Faculty
Sandy Allen-Bard, MSN, NPc, ANCC, AOCNP
Leukemia Nurse Practitioner
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Sandy Allen-Bard, MSN, NPc, ANCC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant for ARIAD Pharmaceuticals, Inc.; Celgene Corporation; and Incyte Corporation.
Advisory Board for ARIAD Pharmaceuticals, Inc. and Celgene Corporation.

Sandy Allen-Bard, MSN, NPc, ANCC, AOCNP, does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

Emily A. Knight, RN, MSN, NP, OCN
Hematology Nurse Practitioner
Mayo Clinic in Arizona
Mayo Clinic Cancer Center
Phoenix, Arizona

Emily A. Knight, RN, MSN, NP, OCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte Corporation.

Emily A. Knight, RN, MSN, NP, OCN does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for myelofibrosis and other myeloproliferative neoplasms.‚Äč

Nurse Reviewer
Pamela Ash, RN, MSN, CBCN
Supportive Care Nurse Clinician
Mary Babb Randolph Cancer Center Clinic
West Virginia University
Morgantown, West Virginia

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hour(s).

Providership

This CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.